FY2025 EPS Estimates for REGENXBIO Cut by Chardan Capital

REGENXBIO Inc. (NASDAQ:RGNX) – Analysts at Chardan Capital reduced their FY2025 earnings estimates for shares of REGENXBIO in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst D. Gataulin now expects that the biotechnology company will post earnings per share of ($3.03) for the year, down from their prior estimate of ($1.39). Chardan Capital has a “Buy” rating and a $52.00 price objective on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Chardan Capital also issued estimates for REGENXBIO’s FY2026 earnings at $4.87 EPS.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.26. The firm had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%.

Other equities analysts have also issued research reports about the company. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. HC Wainwright dropped their price target on REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Monday, March 17th. Morgan Stanley lifted their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, March 14th. Royal Bank of Canada restated an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. Finally, Raymond James started coverage on shares of REGENXBIO in a report on Friday, February 7th. They issued an “outperform” rating and a $27.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, REGENXBIO presently has an average rating of “Moderate Buy” and an average target price of $32.78.

REGENXBIO Stock Performance

Shares of RGNX stock opened at $7.91 on Thursday. The stock has a fifty day simple moving average of $7.39 and a two-hundred day simple moving average of $8.81. The firm has a market capitalization of $396.18 million, a PE ratio of -1.57 and a beta of 1.35. REGENXBIO has a 52-week low of $5.62 and a 52-week high of $22.42.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently bought and sold shares of RGNX. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of REGENXBIO in the 3rd quarter worth about $643,000. Intech Investment Management LLC bought a new stake in REGENXBIO during the third quarter worth approximately $161,000. Charles Schwab Investment Management Inc. raised its position in REGENXBIO by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock valued at $4,382,000 after purchasing an additional 37,055 shares during the period. FMR LLC raised its position in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of REGENXBIO by 602.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 17,533 shares during the last quarter. Institutional investors own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.